Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Silverman

Showing results (751-760 of 816) with videos related to

Pageof 82
Sort By:
The New England Journal of Medicine|April 13, 2012
Outcomes after induction failure in childhood acute lymphoblastic leukemiaMartin Schrappe, Stephen P Hunger, Ching-Hon Pui, et al.
Brain : a Journal of Neurology|September 17, 2015
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph diseaseAndreia Teixeira-Castro, Ana Jalles, Sofia Esteves, et al.
The Lancet. Oncology|June 15, 2016
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensusKjeld Schmiegelow, Andishe Attarbaschi, Shlomit Barzilai, et al.
Blood|December 17, 2009
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemiaLewis B Silverman, Jeffrey G Supko, Kristen E Stevenson, et al.
Leukemia|February 21, 2014
Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemiaC Reynolds, J E Roderick, J L LaBelle, et al.
The American Journal of Gastroenterology|January 13, 2006
Risk factors for post-ERCP pancreatitis: a prospective multicenter studyChi-Liang Cheng, Stuart Sherman, James L Watkins, et al.
Pediatric Blood & Cancer|November 2, 2017
An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001Justine M Kahn, Peter D Cole, Traci M Blonquist, et al.
Pediatric Blood & Cancer|March 22, 2022
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001Uma H Athale, Yael Flamand, Traci Blonquist, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
British Journal of Haematology|December 25, 2025
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challengeAdriana Balduzzi, Maria Grazia Valsecchi, Thai Hoa Tran, et al.
Pageof 82

Showing results (751-760 of 816) with videos related to

Sort By:
Pageof 82
The New England Journal of Medicine|April 13, 2012
Outcomes after induction failure in childhood acute lymphoblastic leukemiaMartin Schrappe, Stephen P Hunger, Ching-Hon Pui, et al.
Brain : a Journal of Neurology|September 17, 2015
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph diseaseAndreia Teixeira-Castro, Ana Jalles, Sofia Esteves, et al.
The Lancet. Oncology|June 15, 2016
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensusKjeld Schmiegelow, Andishe Attarbaschi, Shlomit Barzilai, et al.
Blood|December 17, 2009
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemiaLewis B Silverman, Jeffrey G Supko, Kristen E Stevenson, et al.
Leukemia|February 21, 2014
Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemiaC Reynolds, J E Roderick, J L LaBelle, et al.
The American Journal of Gastroenterology|January 13, 2006
Risk factors for post-ERCP pancreatitis: a prospective multicenter studyChi-Liang Cheng, Stuart Sherman, James L Watkins, et al.
Pediatric Blood & Cancer|November 2, 2017
An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001Justine M Kahn, Peter D Cole, Traci M Blonquist, et al.
Pediatric Blood & Cancer|March 22, 2022
Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001Uma H Athale, Yael Flamand, Traci Blonquist, et al.
Haematologica|February 3, 2022
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)Sarah K Tasian, Lewis B Silverman, James A Whitlock, et al.
British Journal of Haematology|December 25, 2025
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challengeAdriana Balduzzi, Maria Grazia Valsecchi, Thai Hoa Tran, et al.
Pageof 82